Grant received in 2021

DCCC has funded 200.000 DKK to the project

The global increasing incidence of obesity (“globesity”) is a pressing health challenge with cancer regarded an obesity-related comorbidity. Obesity increase cancer risk and is an adverse prognostic indicator, which may reduce the benefit of cancer treatment. The Danish Cancer Society has highlighted the need for increased awareness of the link between obesity and cancer and enhanced research in the field. AIMS: To address this challenge, we initiated a national DCCC-network (2020) and now aim to establish our National Network for Obesity and Cancer Research (ObeCaRe).

The ObeCaRe ambition is to identify preventable pathways for obesity associated cancer progression and improve clinical outcomes among obese cancer patients. A multidisciplinary research approach is needed to address the underlying biological, clinical, and behavioral mechanisms to ultimately provide improved, personalized care for overweight and obese cancer patients to improve cancer prognosis.

Project stakeholders

CAPITAL REGION OF DENMARK

  • ANN KNOOP, Rigshospitalet, Dept. of Oncology; oncology and clinical trials
  • CAMILLA SCHEELE, Copenhagen University, NNF Center for Basic Metabolic Research; adipocyte biology
  • SØREN NIELSEN, Rigshospitalet, Centre for Physical Activity Research; life style intervention
  • CLAUS HØGDALL, Rigshospitalet, Dept. of Gynecology; translational gynecology, chair DCGG
  • CHRISTOFFER JOHANSEN, Rigshospitalet, Dept. of Oncology; psychological oncology

CENTRAL DENMARK REGION

  • DEIRDRE CRONIN FENTON, Aarhus University, Dept. of Clinical Epidemiology; cancer epidemiology
  • TINNE LAURBERG, Aarhus University Hospital, Dept. of Pathology; translational pathology
  • ANNELLI SANDBÆK, Aarhus University Hospital, Dept. of Public Health; general medicine, communication
  • HENRIK TOFT SØRENSEN, Aarhus University, Dept. of Clinical Epidemiology; cancer trials and epidemiology
  • METTE EBBESEN, Aarhus University, Department of Molecular Medicine & Centre for Science Studies; ethics in cancer
  • PETER CHRISTENSEN, Aarhus University Hospital, Dept. of Surgery, pelvic cancer surgery
  • LENE HJERRILD IVERSEN, Aarhus University Hospital, Dept. of Surgery; colorectal cancer, surgery
  • MICHAEL BORRE, Aarhus University Hospital, Dept. of Urology; prostate cancer, intervention trials, chair DMCG
  • ROBERT ZACHARIAE, Aarhus University Hospital, Unit for Psycho-Oncology and Health Psychology; bio-psychosocial cancer research, DCCL board
  • NIELS JESSEN, Aarhus University, STENO Diabetes; clinical/translational endocrinology
  • JENS MELDGAARD BRUUN, Aarhus University Hospital, National Center of Obesity, Dept. of Endocrinology; clinical/experimental obesity
  • SIGNE BORGQUIST, Aarhus University Hospital, Dept. of Oncology; clinical/translational oncology, clinical trials

REGION OF NORTH DENMARK

  • CHARLOTTE BIRKMOSE ROTBØLL, Aalborg University Hospital, Dept. of Oncology; oncology
  • RANDI TOBBERUP, Aalborg University Hospital, Dept. of Oncology; dietician

REGION OF SOUTHERN DENMARK

  • JAN FRYSTYK, Odense University Hospital, University of Southern Denmark; Dept. of Endocrinology, chair; translational endocrinology/obesity
  • MARIANNE EWERTZ, University of Southern Denmark, Dept. of Oncology; clinical breast oncology
  • RIKKE HJORTEBJERG, University of Southern Denmark, Dept. of Experimental Endocrinology; translational obesity
  • PER PFEIFFER, Odense University Hospital, Dept. of Oncology; clinical GI-oncology

INTERNATIONAL ADVISORY BOARD

  • ANDREW RENEHAN, University of Manchester, MANCHESTER CANCER RESEARCH CENTRE; obesity and cancer research
  • ANN ROSENDAHL, Lund University, Dept. of Oncology; translational obesity and cancer
  • CHRISTIAN RASK MADSEN, Harvard Medical School, Joslin Diabetes Center; preclinical obesity, endocrinology and cancer